Engineered immune cells target Virus-Driven cancers in new trial
Disease control
Recruiting now
This early-phase trial is testing a new cell therapy called GP350 CAR-T for adults with certain lymphomas linked to Epstein-Barr virus (EBV) that have relapsed or not responded to standard treatments. Doctors will collect a patient's own immune cells, modify them in a lab to bett…
Phase: PHASE1, PHASE2 • Sponsor: Zhimin Zhai • Aim: Disease control
Last updated Apr 06, 2026 14:18 UTC